<DOC>
	<DOCNO>NCT01823016</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) JNJ-38518168 compare placebo participant persistent asthma inadequately control despite current treatment .</brief_summary>
	<brief_title>A Study JNJ-38518168 Symptomatic Adult Participants With Uncontrolled , Persistent Asthma</brief_title>
	<detailed_description>This study randomize ( treatment group assign chance , like flip coin ) , double-blind ( study investigator participant know treatment administer ) , placebo-controlled ( placebo identical study agent , contain active ingredient ) . A total 160 participant receive either placebo JNJ-38518168 daily . The study duration approximately 32 week include screen phase approximately 4 week , 24-week placebo-controlled treatment phase , 4-week follow-up phase . Participant safety monitor throughout entire study period..</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Have diagnosis asthma least 26 week , confirm investigator Screening Visit 1 Have receive inhale corticosteroid ( ICS ) ( ≤1000 µg/day fluticasone equivalent ) least 12 week prior Screening Visit 1 At Screening Visit 1 , receive dose ICS ≤1000 µg/day fluticasone ( equivalent ) alone conjunction longacting β2agonist ( LABA ) and/or montelukast least 4 week prior screen change dose dose regimen therapy 4 week period prior screen Have Asthma Control Questionnaire ( ACQ ) score ≥1.5 Screening Visit 1 Have prebronchodilator force expiratory volume 1 second ( FEV1 ) equal 40 % 80 % , inclusive , predict value Screening Visit 1 Have ≥12 % relative change ≥200 mL change FEV1 postbronchodilator either Screening Visit 1 2 Has ever lifethreatening asthma attack include respiratory arrest , intubation , intensive care unit ( ICU ) admission due asthma Has history chronic respiratory condition include , limited , chronic obstructive pulmonary disease ( COPD ) , bronchiolitis , bronchiectasis , allergic bronchopulmonary aspergillosis ( mycosis ) , occupational asthma , sleep apnea , pulmonary hypertension , obstructive pulmonary disease Has use follow asthma therapy : systemic corticosteroid within 6 week Screening Visit 1 ; oral betaagonists within 4 week Screening Visit 1 ; cromolyns within 4 week Screening Visit 1 ; leukotriene inhibitor montelukast within 4 week Screening Visit 1 ; theophylline within 4 week Screening Visit 1 ; inhale anticholinergic agent within 4 week Screening Visit 1 ; omalizumab within 130 day Screening Visit 1 Has initiate discontinue allergen immunotherapy within 12 week Screening Visit 1 Has smoke within 3 year Screening Visit 1 history smoking ≥ 10 pack year BodyMass Index ( BMI ) great equal 40 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Uncontrolled , persistent asthma</keyword>
</DOC>